Eagle Pharmaceuticals to Host Fourth Quarter and Full Year
WOODCLIFF LAKE, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the
BRIDGEWATER, N.J., March 15, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that the Company will release its fourth quarter and full year 2022 financial results and provide a commercial update on Monday, March 20, 2023, before U.S. financial markets open.
Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Mike DePetris, Principal Accounting Officer, will host a conference call as follows:
Date | Monday, March 20, 2023 |
Time | 8:30 a.m. ET |
Toll free (U.S.) | 800-343-4136 |
International | 203-518-9814 |
Webcast (live and replay) | ir.rvlpharma.com under the “Investors & News” section |
A replay of the conference call will be available for two weeks after the call's completion by dialing 888-215-1487 (U.S.) or 402-220-4938 (International) and entering conference call ID RVLQ422. The webcast will be archived for 30 days at the aforementioned URL.
*Conference call participants should register to obtain their dial-in and passcode details.
IMPORTANT SAFETY INFORMATION
INDICATION
UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONS
Adverse reactions that occurred in 1-5% of subjects treated with UPNEEQ were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation and headache.
DRUG INTERACTIONS
About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.
Investor and Media Relations for RVL Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com